Cenduit Launches New Professional Services Division
The Professional Services Division, provides hands-on experience for managing and enhancing Interactive Response Technology (IRT) systems.
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, announced its new Professional Services Division, to provide hands-on experience for managing and enhancing Interactive Response Technology (IRT) systems.
Features of the new division include:
- Support with complex third-party system integrations and customizations
- Consulting for complex studies that require focused support
- Protocol-specific consulting (for example, needing an IVR set up where the patient will call in and report adverse events)
- Business analytics and reporting such as forecasting dashboard, enabling with effective decision support system for optimization.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
